Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249085 | 1.00 | PANK3 (0.46) | PANK3AKR1C3KDM4EALDH1A1NPSR1 | |
| SCHEMBL2550594 | 0.89 | PANK3 (0.46) | PANK3KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL2249362 | 0.89 | PANK3 (0.46) | PANK3KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL2252896 | 0.85 | KDM4E (0.55) | PANK3KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL2248062 | 0.85 | KDM4E (0.55) | PANK3KDM4EALDH1A1NPSR1HSD17B10 | |
| SCHEMBL2249244 | 0.81 | LMNA (0.42) | KDM4EALDH1A1NPSR1HSD17B10KMT2A | |
| SCHEMBL2552704 | 0.81 | LMNA (0.42) | KDM4EALDH1A1NPSR1HSD17B10KMT2A | |
| SCHEMBL3873237 | 0.78 | LMNA (0.46) | PANK3AKR1C3KMT2ASMN1; SMN2 | |
| SCHEMBL2246826 | 0.78 | LMNA (0.46) | PANK3AKR1C3KMT2ASMN1; SMN2 | |
| SCHEMBL2551845 | 0.78 | LMNA (0.46) | PANK3AKR1C3KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | PANK3 3763/4885AKR1C3 645/4885KDM4E 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.